Biopsy News and Research

RSS

Biopsy is the removal of cells or tissues for examination by a pathologist. The pathologist may study the tissue under a microscope or perform other tests on the cells or tissue. There are many different types of biopsy procedures. The most common types include: (1) incisional biopsy, in which only a sample of tissue is removed; (2) excisional biopsy, in which an entire lump or suspicious area is removed; and (3) needle biopsy, in which a sample of tissue or fluid is removed with a needle. When a wide needle is used, the procedure is called a core biopsy. When a thin needle is used, the procedure is called a fine-needle aspiration biopsy.

Researchers develop optimised PSA screening programme for prostate cancer

As an indicator of prostate cancer, the PSA test is regarded in urology as highly controversial since it is not always unequivocal. A team of researchers from the Comprehensive Cancer Center at the MedUni Vienna and Vienna General Hospital has now developed a programme that compensates the shortfalls of PSA screening with methods from personalised medicine. As a result, prostate cancer screening is able to reach a new level of quality.

4 Feb 2015

CellDetect urine test for detecting bladder cancer meets primary endpoint in multi-center clinical study

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that a blinded, multi-center clinical study of the CellDetect non-invasive test for detecting bladder cancer in urine, successfully achieved the study's primary endpoint for effectively detecting the recurrence of bladder cancer in subjects with a history of the disease.

3 Feb 2015

New study examines the methylome of triple-negative breast cancer

The new study, published in Nature Communications, compares the breast cancer DNA 'methylome' with that of healthy individuals. The methylome provides a new picture of the genome and shows how it is epigenetically 'decorated' with methyl groups, a process known as DNA 'methylation'.

3 Feb 2015

EKF Molecular Diagnostics collaborates with ANGLE for liquid biopsy development using Parsortix and PointMan technologies

EKF Molecular Diagnostics has agreed a collaboration with specialist medtech company ANGLE plc, to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform with EKF Molecular's PointMan™ DNA enrichment technology as a liquid biopsy. If successful, the resulting simple blood test could enable the investigation of unexpected ultra-low level mutations in a patient's cancer for personalised cancer care.

29 Jan 2015

Gluten-free diet important for people with celiac disease

You'd never suspect it from the proliferation of gluten-free items on supermarket shelves. Yet only one in approximately 133 people - that's 0.75 percent of the population - has celiac disease, a genetic autoimmune disorder that causes the body to react negatively to the intake of gluten, a protein found in wheat, rye, barley and their derivatives.

29 Jan 2015

Primary care physicians unfamiliar with California breast density law, shows UC Davis study

Ten months after California legislators enacted a controversial law mandating that radiologists notify women if they have dense breast tissue, UC Davis researchers have found that half of primary care physicians are still unfamiliar with the law and many don't feel comfortable answering breast density-related questions from patients.

28 Jan 2015

Study: Targeted biopsy technique better than standard biopsy at detecting high-risk prostate cancer

Among men undergoing biopsy for suspected prostate cancer, targeted magnetic resonance/ultrasound fusion biopsy, compared with a standard biopsy technique, was associated with increased detection of high-risk prostate cancer and decreased detection of low-risk prostate cancer, according to a study in the January 27 issue of JAMA.

28 Jan 2015

Mayo Clinic study compares new breast cancer risk prediction model with current model

A new breast cancer risk prediction model combining histologic features of biopsied breast tissue from women with benign breast disease and individual patient demographic information more accurately classified breast cancer risk than the current screening standard.

27 Jan 2015

New imaging technique increases detection rates of invasive breast cancers

A new breast imaging technique pioneered at Mayo Clinic nearly quadruples detection rates of invasive breast cancers in women with dense breast tissue, according to the results of a major study published this week in the American Journal of Roentgenology.

24 Jan 2015

Researchers develop new treatment that extends telomeres

Will extending telomeres lead to longer, healthier lives? Researchers have taken an important step toward answering this question by developing a new treatment used in the laboratory that extends telomeres.

24 Jan 2015

Gensignia's research in CT lung cancer screening recognized by ASCO

Gensignia scientific co-founders' research has been recognized in Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology published online in the Journal of Clinical Oncology (JCO) on January 20, 2015.

22 Jan 2015

Patients who receive lungs from heavy drinkers more likely to develop severe primary graft dysfunction

Lung transplant patients who receive lungs from heavy drinkers are nearly nine times more likely to experience a life-threatening complication called primary graft dysfunction, a Loyola University Medical Center study has found.

20 Jan 2015

Using breath tests to diagnose liver diseases: an interview with Larry Cohen

It was back in the 1960s that scientists first started to understand that breath could be used to find out different things about diseases and other factors. I’m sure you’re familiar with alcohol breath testing, which was patented back in the ‘50s and has been used since the ‘60s.

19 Jan 2015

EKF highlighting heat and humidity compatible POC hemoglobin analyzer at Arab Health 2015

EKF Diagnostics, the global diagnostics company, announces that it will be highlighting the robustness of its new DiaSpect Tm POC hemoglobin analyzer.

From EKF Diagnostics 15 Jan 2015

ArborMetrix's RegistryMetrix analytics platform selected for UNC's urology department

ArborMetrix, Inc., a leading provider of cloud-based healthcare analytics solutions, today announced that the Urology Department of the University of North Carolina School of Medicine is using its cloud-based RegistryMetrix analytics platform.

15 Jan 2015

Duke researchers grow contracting human skeletal muscle in lab

In a laboratory first, Duke researchers have grown human skeletal muscle that contracts and responds just like native tissue to external stimuli such as electrical pulses, biochemical signals and pharmaceuticals.

13 Jan 2015

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

QIAGEN announced today the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples to assess an important genomic mutation in patients with non-small cell lung cancer (NSCLC), the most common form of this cancer.

From QIAGEN Manchester Limited 12 Jan 2015

Pathologists use ProExC antibody cocktail to determine tumor recurrence

Partnering with head and neck surgeons, pathologists at Dartmouth Hitchcock Medical Center's Norris Cotton Cancer Center developed a new use for an old test to determine if a patient's cancer is recurring, or if the biopsy shows benign inflammation of mucosal tissues. In Pathology - Research and Practice, lead author Candice C. Black, DO explained how her team confirmed the utility of ProExC, an existing antibody cocktail commonly used for pathology tests of the uterine cervix.

12 Jan 2015

Mayo Clinic study dispels myth that cancer biopsies cause cancer to spread

A study of more than 2,000 patients by researchers at Mayo Clinic's campus in Jacksonville, Florida, has dispelled the myth that cancer biopsies cause cancer to spread. In the Jan. 9 online issue of Gut, they show that patients who received a biopsy had a better outcome and longer survival than patients who did not have a biopsy.

11 Jan 2015

$ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL$

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258.

8 Jan 2015